The USANA Health Sciences, Inc. (USNA) Price Target Lowered to $75.00 at Pivotal Research, Report finds

The USANA Health Sciences, Inc. (USNA) Price Target Lowered to $75.00 at Pivotal Research, Report finds

Separately, Zacks Investment Research downgraded shares of USANA Health Sciences from a hold rating to a strong sell rating in a research report on Tuesday, November 1st.

USANA Health Sciences, Inc. (NYSE:USNA) had its price objective cut by Pivotal Research from $80.00 to $75.00 in a research note issued to investors on Wednesday. They currently have a buy rating on the stock.

Shares of USANA Health Sciences (NYSE:USNA) traded up 5.60% on Wednesday, hitting $58.50. The stock had a trading volume of 194,924 shares. USANA Health Sciences has a 12-month low of $54.25 and a 12-month high of $75.00. The company has a 50 day moving average of $62.06 and a 200-day moving average of $107.73. The firm has a market capitalization of $1.46 billion, a P/E ratio of 14.66 and a beta of 1.07.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 7th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by $0.07. The company had revenue of $252.90 million for the quarter, compared to analyst estimates of $253.52 million. USANA Health Sciences had a return on equity of 35.36% and a net margin of 9.89%. The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business earned $0.92 earnings per share. Equities analysts predict that USANA Health Sciences will post $4.47 EPS for the current fiscal year.

In related news, Director Myron W. Wentz sold 20,000 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $61.04, for a total value of $1,220,800.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 60,000 shares of company stock worth $3,566,400 over the last three months. 57.00% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jensen Investment Management Inc. purchased a new position in shares of USANA Health Sciences during the third quarter worth about $490,000. Rothschild Asset Management Inc. purchased a new position in shares of USANA Health Sciences during the third quarter worth about $266,000. Old Mutual Global Investors UK Ltd. boosted its position in shares of USANA Health Sciences by 52.8% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 90,316 shares of the company’s stock worth $12,495,000 after buying an additional 31,211 shares during the period. Denali Advisors LLC purchased a new position in shares of USANA Health Sciences during the third quarter worth about $2,194,000. Finally, Algert Global LLC boosted its position in shares of USANA Health Sciences by 81.4% in the third quarter. Algert Global LLC now owns 7,959 shares of the company’s stock worth $1,101,000 after buying an additional 3,572 shares during the period. 20.97% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Related posts

Leave a Comment